Cash-strapped countries are making biopharm consider a product’s fiscal benefits earlier in development, according to INC.
Shifts in global economics mean that countries and companies alike are facing restrictions on spending. In this economic environment biopharm must be ready to answer certain questions when seeking to commercialise a product.
“Do we invest in your product if there’s no fiscal benefit compared to the incumbent product? That’s becoming more and more, unofficially, a view that many countries are taking”, said Geoff Fatzinger, director of regulatory affairs and strategic product development at INC Research.
Fatzinger is responsible for Europe, Asia Pacific and the Middle East and fiscal considerations vary significantly across these regions. For example, emerging countries in Asia Pacific have large populations and finite resources, making them particularly keen to see return on investment.